Concepedia

Andrew Payne

AP

11

Publications

414

Citations

11

H-Index

1994

Active since

Affiliations

UCB Pharma (United Kingdom)(Current)

Centre National de la Recherche Scientifique

Inserm

NIHR Birmingham Biomedical Research Centre

University of Birmingham

Andrew Payne is an author at UCB Pharma (United Kingdom) specializing in medicine, drug discovery, and medicinal chemistry.

Top concepts

Publications per year

1994–2020

11

Publications

11

Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors

John Porter, Andrew Payne, Ben de Candole et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 117 citations · Full text

, , +4

Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome

Saba Nayar, Joana Campos, Charlotte G. Smith et al. · Annals of the Rheumatic Diseases · 2018 · 44 citations · Full text

Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ

Rodger A. Allen, Daniel C. Brookings, Mark Powell et al. · Journal of Pharmacology and Experimental Therapeutics · 2017 · 44 citations

A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome

Maria Juárez, Nieves Díaz, Geoffrey I. Johnston et al. · Lara D. Veeken · 2020 · 42 citations · Full text

Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases

Sijia Chen, Ross A. Paveley, Lianne Kraal et al. · Journal of Autoimmunity · 2020 · 31 citations · Full text

, , +24

Rows per page

1–5 of 11